According to the research report titled ‘Global Rheumatoid Arthritis Market (2021 Edition) - Analysis By Drug Type (NSAIDs, DMARDs, Corticosteroids, Others), Treatment, Diagnosis, By Region, By Country: Market Insights and Forecast with Impact of COVID-19 (2021-2026)’, available with MarketStudyReport, global rheumatoid arthritis market is expected to expand exponentially through the analysis timeframe.

Rising geriatric population and the prevalence of smoking leading to increase in cases of rheumatoid arthritis are the major factors aiding the augmentation in the global rheumatoid arthritis market.

Request sample copy of this report: https://www.marketstudyreport.com/request-a-sample/4383305/

Further, various initiatives funded by WHO and NIH aimed towards the prevention & treatment of chronic diseases such as cardiovascular ailments and rheumatoid arthritis, as well as R&D activities carried out by academic institutions are likely to propel the industry in the forthcoming years.

Speaking of treatment type, the industry is divided into joint replacement, joint fusion, tendon replacement, and others. While as per diagnosis, worldwide rheumatoid arthritis industry is classified into erythrocyte sedimentation rate (ESR), C-reactive protein test (CRP), and others.

Based on drug type, the market is categorized into corticosteroids, DMARDs (disease mortifying nti-rheumatic drug), NSAID (non-steroidal anti-inflammatory drugs), and others. Of these, DMARDs segment is slated to experience an upward growth trend over the analysis period, creditable to the increase in the number of patients with rheumatoid arthritis, emergence of therapeutic agents, and favorable reimbursement policies.

From a regional standpoint, Americas held the largest market share in 2020 and is slated to continue to foresee a significant growth through 2026, attributable to penetration of biopharmaceuticals for treatment, advanced healthcare infrastructure, growing awareness regarding the disease, and mounting geriatric population in the landscape.

Considering the competitive framework, Johnson & Johnson, Merck KGaA, Cipla Ltd., Sanofi S.A., F. Hoffman-La Roche AG, Galapagos N.V., Pfizer Inc., Gilead Sciences Inc., and Bristol Myers Squibb are the prominent players influencing global rheumatoid arthritis market trends.   

These companies are focusing on improving their production capacity by diverting their resources towards R&D activities so as to meet the burgeoning demand of consumers and elevate their position in the marketplace.